TEGOSCIENCE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21,550 KRW | -2.93% |
|
-2.93% | +47.00% |
| 2023 | TegoScience Inc.(KOSDAQ:A191420) dropped from S&P Global BMI Index | CI |
| 2023 | TegoScience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| Sales 2022 | 7.68B 5.54M 7.63M | Sales 2023 | 7.77B 5.61M 7.73M | Capitalization | 117B 84.75M 117M |
|---|---|---|---|---|---|
| Net income 2022 | 265M 191K 263K | Net income 2023 | -2.32B -1.68M -2.31M | EV / Sales 2022 | 9.97 x |
| Net cash position 2022 | 21.16B 15.28M 21.03M | Net cash position 2023 | 19.37B 13.99M 19.25M | EV / Sales 2023 | 12.6 x |
| P/E ratio 2022 |
370
x | P/E ratio 2023 |
-50.6
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 56.75% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.93% | ||
| 1 week | -2.93% | ||
| Current month | -3.58% | ||
| 1 month | -3.58% | ||
| 3 months | +88.05% | ||
| 6 months | +181.70% | ||
| Current year | +47.00% |
1 week
21 300.00
23 400.00
1 month
17 500.0025 700.00
Current year
10 710.0025 700.00
1 year
7 430.0025 700.00
3 years
7 430.0031 300.00
5 years
7 430.0037 400.00
10 years
7 430.0073 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sae-Wha Jeon
FOU | Founder | 58 | 01-03-19 |
| 61 | - | ||
Han-Kyu Jang
BRD | Director/Board Member | 51 | 01-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sae-Wha Jeon
FOU | Founder | 58 | 01-03-19 |
Jae-Wook Jeon
FOU | Founder | 61 | 01-03-19 |
Han-Kyu Jang
BRD | Director/Board Member | 51 | 01-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 21,550 | -2.93% | 13,842 |
| 24-04-29 | 22,200 | +0.68% | 30,969 |
| 24-04-26 | 22,050 | +0.68% | 18,290 |
| 24-04-25 | 21,900 | -4.16% | 13,736 |
| 24-04-24 | 22,850 | -1.08% | 11,072 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
Tego Science,Inc. is a Korea-based company mainly engaged in the research and development, manufacture and distribution of wound-healing skin cell therapy products. The Companyâs products mainly consist of cell therapy products, and laboratory cultured skin models.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +47.00% | 125M | |
| -4.14% | 86.85B | |
| +2.76% | 40.16B | |
| -16.48% | 31.28B | |
| +57.86% | 25.27B | |
| -13.58% | 15.33B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| +6.89% | 8.83B | |
| -10.18% | 7.94B |
- Stock Market
- Equities
- A191420 Stock
